

About JZCP

JZCP is a London listed private equity fund which invests in high quality US and European micro cap companies. It receives investment advice from Jordan/Zalaznick Advisers, Inc. ("JZAI"), which works with the existing management of micro cap companies to help build better businesses, create value and deliver strong returns to investors.

Investment Objective

JZCP seeks to create a portfolio of investments in businesses in the United States and Europe, providing a superior overall return comprised of a current yield and significant capital appreciation.

Recent Events

- On 28 March 2013, JZCP invested \$7.6 million in RIS Holdings, Inc. (Mid-American Machine & Equipment, Inc.)
- On 28 March 2013, JZCP received \$33.7 million from the sale of BG Holdings, Inc. (Horsburgh & Scott Co.)




Company Summary			
		Zero Dividend	
		Preference	
	Ordinary Shares	("ZDP") Shares	
Number of Shares	65,018,607	20,707,141	
NAV (\$000's) in USD	\$633,406	n/a	
NAV per Share in USD	\$9.74	n/a	
NAV per Share in GBP	£6.42	n/a	
ZDP Value (£000's) in GBP	n/a	£59,669	
ZDP Value per Share	n/a	£2.88 ₍₁₎	
Quoted Market Price			
(End of Month) in GBP	£5.34	£3.20	
Market Capitalization			
(\$000's) in GBP	£347,199	£66,159	
Quoted Market Price			
(End of Month) in USD	\$8.11 (2)	n/a	
Market Capitalization			
(\$000's) in USD	\$527,205 (2)	\$100,460 (2)	
Premium / (Discount)			
to NAV per Share	(16.8%)	n/a	
Premium / (Discount)			
to ZDP Value per Share	n/a	10.9%	
Currency in quotation	GBP	GBP	
Ticker	JZCP	JZCN	

Top 10 Holdings (Excluding Cash & Equivalents)

Investment			% of
	Туре	Value \$(3)	Total
Safety Insurance Group, Inc.	Listed Equities	56,873	10%
Factor Energia, S.A.	uropean Investments	51,107	9%
Dental Services Group, Inc.	US Micro Cap	27,204	5%
Accutest Holdings, Inc.	US Micro Cap	27,043	5%
Grupo Ombuds E	uropean Investments	24,762	4%
Amptek, Inc.	US Micro Cap	21,110	4%
Bay Valve Services	US Micro Cap	20,743	4%
TWH Water Treatment Ind, In	us Micro Cap	20,114	3%
Healthcare Products Holdings,	, Inc. US Micro Cap	20,104	3%
MedPlast Holdings, Inc.	US Micro Cap	18,413	3%
Top 10 Holdings (Ex. Cash	\$287,473	50%	
Remaining Holdings (Ex. Cash	& Equivalents)	\$288,696	50%
Total Holdings (Ex. Cash &	\$576,169	100%	



Summary of Portfolio



Total Private Investments

	Number	Fair Value \$(3)	% to Total
• US Micro Cap	29	318,709	43%
European Investments	5	106,791	15%
• Mezzanine	4	11,384	2%
• Real Estate	3	32,030	4%
• Other	4	11,397	2%
Total	45	\$480,311	66%


Total Listed Investments (including Cash & Equivalents)

	Number	Fair Value \$(3)	% to Total
 Listed Equities 	2	57,715	8%
 Listed Corporate Bonds 		26,426	3%
• Bank Debt	1	11,717	2%
• Cash		126,818	17%
 UK Treasury Gilts 		31,916	4%
Total	3	\$254,592	34%

Total Investments Assets (including Cash & Equivalents)

	Number	Fair Value \$(3)	% to Total
Total	48	\$734,903	100%

Share growth



Contacts

Manager Jordan/Zalaznick Advisers, Inc. Ernst & Young LLP 767 Fifth Avenue PO Box 9 New York, NY 10153

Auditor Royal Chambers St. Julian's Avenue St. Peter Port Guernsey, GY1 4AF

Registrar Equiniti Limited. Aspect House Spencer Road Lancing West Sussex BN99 6ZX

Administrator

Northern Trust International Fund Administration Services (Guernsey) Limited Trafalgar Court Les Banques St. Peter Port Guernsey GY1 3QL

If you want more information regarding JZCP, please call Tom Willetts at FTI Consulting at +44 (0)20 7269 7175.

Disclaimer

This Monthly Fact Sheet updates as of 31 March 2013 various information as to JZCP and its investment portfolio available from third parties whilst continuing as of 28 February 2013 the valuations shown above (and as included in the NAV) for Micro-Cap and unquoted Unaffiliated Mezzanine investments as reported in the financial statements to be issued 20 May 2013. Before making investment decisions, investors should consider that the value of JZCP's investments, and the income from them, may go down as well as up and is not guaranteed; that the market price for JZCP shares, depending on supply and demand, may trade at a discount to NAV; and that past performance cannot be relied upon as a guide to future performance. Investors should also consult with their own independent financial and tax advisers when making investment decisions. Although issued and approved by JZCP, this Monthly Fact Sheet does not constitute a solicitation or advice to buy or sell any security.

Footnotes

- (1) Represents accreted balance as of 31 March 2013
- (2)Assumes an exchange rate as of 31 March 2013 of \$1.52 to £1.00.
- USD in thousands (3)

Company Summary March 2013 www.jzcp.com